GeneDx Holdings (WGS) Current Deferred Revenue (2020 - 2022)

GeneDx Holdings (WGS) has 3 years of Current Deferred Revenue data on file, last reported at $40000.0 in Q4 2022.

• Current Deferred Revenue for Q4 2022 came in at $40000.0, down 91.54% year-over-year; the trailing twelve-month figure through Dec 2022 was $40000.0 (down 91.54% YoY), and the FY2022 annual result was $40000.0, down 91.54% from the prior year.
• Current Deferred Revenue fell to $40000.0 in Q4 2022 per WGS's latest filing, from $100000.0 in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $2.8 million in Q1 2021 and troughed at $40000.0 in Q4 2022.
• A 3-year average of $1.0 million and a median of $493000.0 in 2021 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2021 and 2022: Current Deferred Revenue sank 73.72% in 2021, then slumped 96.44% in 2022.
• A 3-year view of Current Deferred Revenue shows it stood at $1.8 million in 2020, then slumped by 73.72% to $473000.0 in 2021, then tumbled by 91.54% to $40000.0 in 2022.
• Business Quant data shows WGS's Current Deferred Revenue at $40000.0 in Q4 2022, $100000.0 in Q1 2022, and $473000.0 in Q4 2021.